Thymopoietin Or Lipotropin; Related Peptides Patents (Class 530/301)
-
Publication number: 20130210724Abstract: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.Type: ApplicationFiled: April 12, 2013Publication date: August 15, 2013Applicant: Cerulean Pharma Inc.Inventor: Cerulean Pharma Inc.
-
Patent number: 8426555Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.Type: GrantFiled: October 9, 2009Date of Patent: April 23, 2013Assignee: Dinona Inc.Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
-
Patent number: 8263551Abstract: The present invention relates to pharmaceutical formulations comprising insulin, an insulin analog, an insulin derivative, or a combination of any of the foregoing, and a salt of protamine, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the insulin peptide(s) contained in such formulations is indicated. The present invention further relates to methods for increasing the stability and/or solubility of insulin in insulin-containing formulations at a pH less than 7.0 by adding a salt of protamine to the insulin-containing formulations.Type: GrantFiled: November 21, 2005Date of Patent: September 11, 2012Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Niels Christian Kaarsholm, Per Balschmidt
-
Publication number: 20120070897Abstract: Provided is a factor capable of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time. More particularly, provided are a method of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time by adding a compound derived from proopiomelanocortin (POMC) to an undifferentiated (nucleated) erythrocyte, and an enucleation inducer including the compound.Type: ApplicationFiled: February 23, 2010Publication date: March 22, 2012Inventors: Toshihisa Hatta, Eriko Shimamura, Hiroki Shimada
-
Publication number: 20080227205Abstract: The invention provides methods and compositions for in vivo incorporation of non-naturally encoded amino acids into polypeptides by Pseudomonas species and strains derived therefrom. Also provided are compositions including proteins with non-naturally encoded amino acids made by Pseudomonas species and strains derived therefrom.Type: ApplicationFiled: June 2, 2006Publication date: September 18, 2008Applicant: AMBRX, INC.Inventor: Ho Sung Cho
-
Patent number: 7192714Abstract: The invention provides methods and compositions for modeling and detecting LDL receptor transmembrane signaling by detecting proteolysis of an LDL receptor transmembrane domain. The method comprises the steps of: a) providing a sample comprising a cell membrane comprising (i) a polypeptide comprising an LDL receptor transmembrane domain fused to a C-terminal tail, and (ii) a protease which specifically cleaves the domain and thereby releases the tail from the membrane; b) incubating the sample under conditions wherein the protease cleaves the domain and thereby releases the tail from the membrane; and c) detecting a resultant released tail.Type: GrantFiled: October 12, 2001Date of Patent: March 20, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Joachim Herz, Petra May
-
Patent number: 6861504Abstract: The present invention relates to compounds that are capable of modulating CD154 mobilization and that are useful for stabilizing the thrombotic process and reducing the activation of cells involved in an inflammatory response. The present invention also relates to methods useful for identifying such compounds. The present invention also relates to the treatment of platelets for transfusion with metalloproteinase inhibitors to treat or prevent inflammation. The present invention also includes compositions and methods to treat injury and disease related to such biological processes.Type: GrantFiled: November 30, 2001Date of Patent: March 1, 2005Assignees: CBR, Inc., Millenium Pharmaceuticals, Inc.Inventors: David Phillips, Patrick Andre, Denisa D. Wagner
-
Patent number: 6852834Abstract: Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods that produce high yields (e.g., milligram levels) of purified proteins, thereby yielding sufficient purified product for multiple assays and analyses. The high throughput purification technique is simpler and less expensive than current commercial high throughput purification methods, since it requires only one transfer of purification intermediates to a new multiwell plate.Type: GrantFiled: March 20, 2001Date of Patent: February 8, 2005Inventor: Ashutosh Chilkoti
-
Patent number: 6649171Abstract: The invention provides BASB021 polypeptides and polynucleotides encoding BASB021 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: December 8, 2000Date of Patent: November 18, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventor: Joelle Thonnard
-
Patent number: 6465259Abstract: A method for quantitatively and/or qualitatively assaying an analyte in a sample, wherein the analyte is a receptor binding compound, has low detection limits equivalent to those of radioreceptor assays. The method comprises the steps of a) contacting the sample with material comprising a receptor for the analyte in order for receptor-analyte binding to occur and b) further contacting the sample with a detectable ligand for the receptor in order for receptor-ligand binding to occur, followed by c) separating the resulting receptor bound and free fractions, d) subjecting the receptor bound fraction to dissociating conditions releasing the ligand from the receptor and e) assaying for the dissociated ligand in a manner known per se for the detection of the detectable ligand.Type: GrantFiled: May 6, 1999Date of Patent: October 15, 2002Assignee: Merska B.V.Inventors: Maria Johanna Janssen, Kornelis Ensing, Rokus Arie De Zeeuw
-
Patent number: 6428967Abstract: The invention provides methods and compositions for inducing and detecting signal transduction through LDL receptors, including specifically detecting a stress that alters a functional interaction of a low density lipoprotein (LDL) receptor binding polypeptide with an LDL receptor interaction domain, by (a) introducing a predetermined stress into a system which provides a physical interaction of an LDL receptor binding polypeptide with an LDL receptor intracellular binding polypeptide interaction domain, whereby the system provides a stress-biased interaction of the binding polypeptide and the interaction domain, wherein the absence of the stress, the system provides a unbiased interaction of the binding polypeptide and the interaction domain; and (b) detecting the stress-biased interaction of the binding polypeptide and the interaction domain, wherein the binding polypeptide is selected from SEMCAP-1, JIP-1, PSD-95, JIP-2, Talin, OMP25, CAPON, PIP4,5 kinase, Na channel brain 3, Mint1, ICAP-1 and APC subunit1Type: GrantFiled: May 1, 2000Date of Patent: August 6, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Joachim Herz, Michael Gotthardt
-
Patent number: 5955055Abstract: Vascular disease including asymptomatic atherosclerosis can be diagnosed by administering a synthetic peptide or peptide analog having an affinity for, and propensity to accumulate at, a site of vascular injury to a patient, and then detecting the location of the peptide or peptide analog within the patient's vascular system. The synthetic peptide or peptide analog may include an amino acid sequence sufficiently duplicative of the amino acid sequence of a region of either the apolipoprotein B, apolipoprotein A-I, or elastin proteins such that the peptide or peptide analog accumulates at a site of vascular injury.Type: GrantFiled: June 6, 1995Date of Patent: September 21, 1999Assignee: New England Deaconess Hospital CorporationInventors: Robert S. Lees, Ann M. Lees, Allan Fischman, Ing-Lung Shih, Mark A. Findeis
-
Patent number: 5891847Abstract: Retinal dystrophies are treated by melanotropin peptides or analogs.Type: GrantFiled: November 27, 1995Date of Patent: April 6, 1999Assignee: Ramot University Authority for Applied Research and Industrial Development Ltd.Inventor: Nava Naveh
-
Patent number: 5783557Abstract: The invention relates to analogs of thymic humoral factor .gamma.2 (THF-.gamma.2) having at least 4 amino acid residues and corresponding to the sequence of THF-.gamma.2 of the formula I:Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu Ibut differing therefrom by addition, deletion or substitution of one or more amino acid residues, or by cyclization, or by linkage of two or more sequences (I) or modified sequences (I) either directly or through a peptidic or non-peptidic chain.The THF-.gamma.2 analogs of the invention and the functional derivatives and salts thereof are for use as immunomodulatory in pharmaceutical compositions.Type: GrantFiled: March 29, 1996Date of Patent: July 21, 1998Assignee: Yeda Research and Development Company Ltd at Weizmann Institute of ScienceInventors: Yigal Burstein, Nathan Trainin
-
Patent number: 5610272Abstract: 4-methyloxybenzyloxycarbonyl (Moz) is used to protect the alpha amino groups of the amino acids used in solid-phase synthesis of thymosin .alpha..sub.1. It was found that the Moz group can be removed rapidly and completely with 5-10% trifluoroacetic acid in CH.sub.2 Cl.sub.2. Some advantages of utilizing Moz-amino acids over Boc-amino acids in solid-phase peptide synthesis are higher yields and purities with reduced consumption of trifluoroacetic acid during the acidolytic cleavage of the N.sup..alpha. -Moz groups. Further improvements with respect to the recovery and recycling of the used solvent are obtained by using tributylamine in place of triethylamine as the neutralization agent making it possible to distill methylene chloride from the liquid waste without contamination by the lower boiling triethylamine. Methylbenzhydrylamine resin is the preferred resin support. Cleavage from the resin support and deprotection of the protected side groups of the protected thymosin .alpha..sub.Type: GrantFiled: April 15, 1991Date of Patent: March 11, 1997Assignee: Alpha-1 Biomedicals, Inc.Inventor: Su S. Wang
-
Patent number: 5585352Abstract: A method of reducing toxicity of endotoxin in a mammal including the administration of an endotoxin-reducing effective amount of T.alpha..sub.1 to the mammal.Type: GrantFiled: June 10, 1994Date of Patent: December 17, 1996Assignee: The George Washington University Medical CenterInventors: Allan J. Goldstein, Mirela O. Fagarasan
-
Patent number: 5275814Abstract: A protein conjugate or mixture useful in immunotherapy composed of a biological response modifier (BRM) and an allergen is disclosed. In use the protein conjugate or mixture is combined with a pharmaceutically acceptable carrier. Cytokines, bacterial, fungal and viral immunopotentiators and thymus hormones are disclosed as suitable BRM's for use in the invention.Type: GrantFiled: July 10, 1991Date of Patent: January 4, 1994Assignee: Allergy Immuno Technologies, Inc.Inventor: Aristo Wojdani
-
Patent number: 5140010Abstract: The present invention provides a method for preparing aqueous formulations of thymopentin, which method permits the peptide to retain its biological activity during storage at room temperature.Type: GrantFiled: March 6, 1991Date of Patent: August 18, 1992Assignee: Immunobiology Research InstituteInventors: Gideon Goldstein, Tapan Audhya
-
MB-35 a peptide enhancing the production of growth hormone and prolactin from the anterior pituitary
Patent number: 5132401Abstract: A peptide of the formula ##STR1## has been isolated from thymosin fraction 5 (TF-5) and synthetically produced. This peptide, which has 100% homology with a region of histone 2A is able to stimulate and enhance the production of growth hormone (GH) and prolactin (PRL) by anterior pituitary cells. The peptide can be used alone or in combination with another growth hormone stimulant, such as growth hormone releasing factor (GRF), or prolactin hormone stimulant, such as thyrotropin releasing hormone (TRH) to increase the production of GH and PRL beyond that achievable with GRF and TRH alone.Type: GrantFiled: September 19, 1989Date of Patent: July 21, 1992Assignee: George Washington University, Office of Sponsored ResearchInventor: Mahnaz Badamchian -
Patent number: 5094950Abstract: A compound of the formula II: ##STR1## wherein n is an integer of 2 to 10, A' is a bivalent linking group formed by reacting both the reactive groups of a cross linking reagent, andB is a residue of a polypeptide compound, and physiologically acceptable salts thereof are disclosed. Such compound is useful as a non-radioactive carrier for radioactive metal elements.Type: GrantFiled: June 5, 1989Date of Patent: March 10, 1992Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Susumu Kondo, Miki Kurami, Makoto Azuma
-
Patent number: 4923964Abstract: The present invention is directed to the protein human splenin (hsP), substantially free of material associated with the protein in its natural environment in the human spleen. In particular, the present invention relates to such isolated or synthesized human splenin having the amino acid residue sequence:-GLY-LEU-PRO-LYS-GLU-VAL-PRO-ALA-VAL-LEU-THR-LYS-GLN-LYS -LEU-LYS-SER-GLU-LEU-VAL-ALA-ASN-ASN-VAL-THR-LEU-PRO-ALA -GLY-GLU-MET-ARG-LYS-ALA-VAL-TYR-VAL-GLU-LEU-TYR-LEU-GLY -SER-LEU-THR-ALA-GLU-HIS-.Additionally, the present invention relates to a therapeutic composition of matter comprising a therapeutically effective amount of the hsP having the above sequence and a pharmaceutically acceptible carrier.Type: GrantFiled: May 22, 1987Date of Patent: May 8, 1990Assignee: Ortho Pharmaceutical CorporationInventors: Gideon Goldstein, Tapan Audhya
-
Patent number: 4904643Abstract: Thymolymphotropin, a thymus derivative able to stimulate the differentiation and the function of T-lymphycytes, is active after oral administration and can be prepared through a process of partial acid lysis of mammal thymuses. Pharmaceutical compositions containing thymolymphotropin are utilized in the treatment of primary and secondary immunodeficiencies.Type: GrantFiled: June 11, 1987Date of Patent: February 27, 1990Assignee: Ellem Industria Farmaceutica, s.r.l.Inventors: Brunetto Brunetti, Marco Prada
-
Patent number: 4826680Abstract: A pharmaceutical composition is described, which contains a fraction consisting of low molecular proteins and/or oligo peptides, and a yellow fraction containing riboflavine, which is associated with organ specific oligo peptides, which fractions are obtainable by fractionation of thymus extract. This composition has a significant immuno stimulating activity, and can be used for the treatment of immuno deficiency diseases, as for example, for T-cell-deficiencies.Type: GrantFiled: October 22, 1986Date of Patent: May 2, 1989Assignee: Dr. Kurt Mulli Nachf. GmbH & Co. KGInventor: Karl-Heinz Jaeger
-
Patent number: 4711952Abstract: Novel peptide analogs of the serum thymic factor are disclosed, structurally modified, in comparison with the natural substance, both in their N-terminal and C-terminal parts and inside the amino-acid sequence, corresponding to the general formula IA-Gly-Gly-Ser-Asn-B-C-NH-R (I),in which A is pGlu, Gln, Ala-Lys-Ser-Gln, pGlu-Ala-Lys-Ser-Gln or Gln-Ala-Lys-Ser-Gln, B and C are Gly, Phe, Leu, Ala or a direct bond, and R is H, an alkyl with 1 to 6 carbon atoms or a 2-phenylethyl. Depending upon their chemical structure, the subject thymic factor analogs possess either agonistic (immunostimulative) or antagonistic (immunosuppressory) properties.Type: GrantFiled: June 17, 1986Date of Patent: December 8, 1987Assignee: SPOFA, spojene podniky pro zdravotnickouvyrobuInventors: Evzen Kasafirek, Martin Cerny, Petr Kocis, Jiri Krepelka, Jozef Rovensky
-
Patent number: 4696915Abstract: Parathymyosin alpha is a novel peptide isolated from mammalian thymus and contains approximately 105 amino acid residues. It bears a high degree of homology to prothymosin alpha both in sequence and amino acid composition. Parathymosin alpha acts as a blocker or modulator or prothymosin alpha activity.Type: GrantFiled: November 4, 1985Date of Patent: September 29, 1987Assignee: Hoffmann-La Roche Inc.Inventor: Bernard L. Horecker
-
Patent number: 4659694Abstract: A new biological polypeptide hormone has been isolated from mammalian thymus and has been given the designation prothymosin alpha. This peptide contains approximately 107 to 113 amino acid residues depending on species and is distinguished by having the thymosin alpha.sub.1 sequence at its amino-terminus. Prothymosin alpha appears to represent the native polypeptide from which thymosin alpha.sub.1, thymosin alpha.sub.11 and other fragments are generated during the isolation of thymosin fraction 5. Prothymosin alpha is one of several peptides isolated from thymic tissue which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide appears to be more potent on a weight basis than thymosin alpha.sub.1 in the protection of subject animals against opportunistic infections.Type: GrantFiled: August 13, 1984Date of Patent: April 21, 1987Assignee: Hoffmann-La Roche Inc.Inventor: Bernard L. Horecker
-
Patent number: 4621135Abstract: Novel peptide materials having thymic humoral activity are disclosed having the respective amino acid sequences of:Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu;His-Pro-Leu-Pro-Asp-Leu-Tyr; andPhe-Val-LeuThese novel peptides can be isolated from natural thymus glands or can be prepared synthetically.Type: GrantFiled: June 6, 1985Date of Patent: November 4, 1986Assignee: Yeda Research & Development Company, Ltd.Inventors: Nathan Trainin, Yigal Burstein
-
Patent number: 4614731Abstract: A new biologically active polypeptide hormone has been isolated from calf thymosin fraction 5 and has been given the designation thymosin alpha.sub.11. The peptide contains seven additional amino acid residues at the carboxy terminus when compared to thymosin alpha.sub.1. Thymosin alpha.sub.11 is one of several peptides present in thymosin fraction 5 which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide is approxomately 16 times as potent in the protection of subject animals against opportunistic infections as thymosin fraction 5 and approximately equal in potency to thymosin alpha.sub.1.Type: GrantFiled: June 10, 1985Date of Patent: September 30, 1986Assignee: Hoffmann-La Roche Inc.Inventor: Bernard L. Horecker
-
Patent number: 4612365Abstract: Peptide fragments of the alpha thymosin molecule, ranging from four to eighteen peptides in length, and salts thereof, are disclosed. These fragments possess immunostimulatory and immunoregulatory properties similar to the alpha thymosin molecule, and are useful in the same fashion as in this molecule.Type: GrantFiled: April 2, 1984Date of Patent: September 16, 1986Assignee: Max-Planck-Gesellschaft zur Foederung der WissenschaftenInventors: Christian Birr, Ulrich Stollenwerk, deceased, Paul Stollenwerk, heir, Margot Stollenwerk, heir, Ilona Werner
-
Patent number: RE32895Abstract: Valuable new and widely used compositions of matter are comprised of products having enhanced solubility and increased dispersant and the like surfactant activity which products are resulfonated units of alkaline oxidized, hydrolyzed, partially desulfonated lignosulfonates.Type: GrantFiled: September 17, 1981Date of Patent: March 28, 1989Assignee: Reed Lignin, Inc.Inventors: William J. Detroit, Michael E. Sanford